Company news
Abeona Therapeutics Inc. news in 2020
Abeona Therapeutics Inc.'s news releases, calls and decks from 2020, newest first.
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
December 20, 2020
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
October 26, 2020
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
October 5, 2020
Abeona Therapeutics Announces Leadership and Board Transitions
September 27, 2020
Abeona Therapeutics to Participate in Upcoming Investor Conferences
September 7, 2020
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
August 16, 2020
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
August 9, 2020
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
July 9, 2020
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
July 8, 2020
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
July 7, 2020
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
June 17, 2020
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
June 16, 2020
Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
May 27, 2020
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
May 5, 2020
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
April 20, 2020
Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 20, 2020
Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic
March 26, 2020
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
March 16, 2020
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates
March 15, 2020
Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 25, 2020
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
February 11, 2020
Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa
January 20, 2020
Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids
January 14, 2020
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
January 12, 2020